CFA
UTHR icon

Camarda Financial Advisors’s United Therapeutics UTHR Stock Holding History

Camarda Financial Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,966
Closed -$1.55M – 246
2017
Q2 		$1.55M Buy
11,966
+186
+2% +$23.2K 1.66% 19
2017
Q1 		$1.59M Buy
+11,780
New +$1.78M 1.56% 25

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Camarda Financial Advisors's UTHR Position: Q3 2017 in Review

Camarda Financial Advisors sold out of United Therapeutics (UTHR) in Q3 2017, closing a stake of 11,966 shares — an estimated $1.55M sold.

Camarda Financial Advisors first reported a position in UTHR in Q1 2017 and held it in 2 quarters. The position peaked at $1.59M in Q1 2017. 373 funds tracked by Wall St. Rank hold UTHR as of Q3 2017.

  • Camarda Financial Advisors reported no remaining United Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Camarda Financial Advisors sold 11,966 United Therapeutics shares in Q3 2017, an estimated $1.55M.
  • Camarda Financial Advisors first reported a position in United Therapeutics in Q1 2017 and held it in 2 quarters.
  • Camarda Financial Advisors's United Therapeutics position peaked at $1.59M in Q1 2017.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2017.

Based on Camarda Financial Advisors's 13F filing for Q3 2017, filed 15 Nov 2017.